GCAR and the Pancreatic Cancer Action Network (PanCAN) have forged a strategic alliance to leverage features from Precision Promise — a PanCAN-sponsored, master protocol clinical trial platform to test multiple regimens in metastatic pancreatic cancer — to launch the next phase of this groundbreaking effort, a new master protocol for pancreatic cancer sponsored by GCAR.
This effort will continue to accelerate research to address the urgent need for new and more effective therapies for pancreatic cancer patients.
Pancreatic cancer is the third leading cause of cancer-related deaths in the United States.
A NEXT GENERATION PLATFORM TRIAL
This new trial will build upon the valuable insights gained by PanCAN to date and enlists GCAR’s extensive experience in conducting patient-centric master protocols and adaptive platform trials.
- Increased efficiency and scalability through streamlined operations
- Expanded access to a diverse patient population through potential for site and regional growth
- Tailored approach for enhanced pharmaceutical and biotech clinical development
- Powered by GCAR’s track record of innovating, operationalizing, and implementing the modernization of new clinical trial designs
- Strengthened by PanCAN’s unparalleled disease expertise and relationships with the pancreatic cancer community
- Complemented by PanCAN’s Patient Services program, which ensures that patients understand their treatment options
A powerful alliance to fuel new opportunities for innovation, growth, and impact, and most importantly the advancement of new treatments for patients with pancreatic cancer.
Follow us on social media for trial updates and progress.